CDK2 degrader

Oxford, United Kingdom & San Jose, California | April 9, 2026 Oxford BioTherapeutics (OBT) has announced a strategic collaboration...

WATERTOWN, Massachusetts, April 9, 2026 Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license...